534 Views | 370 Downloads
Correspondence to: Lawrence S. Phillips, M.D., Atlanta VA Medical Center, 1670 Clairmont Road, Room 11C-110A, Decatur, GA 30033, p 404-728-7608, f 404-727-1300, medlsp@emory.edu.
YY and LP researched the data, QL performed the statistical analyses, YY drafted the manuscript, and LP, AT, SJ, DO, MR, and all of the other authors contributed to the discussion and reviewed/edited the manuscript.
The authors gratefully acknowledge the contributions of Christine Jasien, Atlanta VAMC who assisted the authors with obtaining VINCI data.
We also acknowledge Qing He, Emory School of Public Health, for assistance with data analysis.
With regard to potential conflicts of interest, within the past five years, Dr. Phillips has served on Scientific Advisory Boards for Boehringer Ingelheim, Profil and Janssen, and has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Glaxo SmithKline, Janssen, Vascular Pharmaceuticals, Glaxo SmithKline, Astra Zeneca, and the Cystic Fibrosis Foundation. In the past, he was a speaker for Novartis and Merck, but not for the last five years.
Darin E Olson has research support from Novo Nordisk and Amylin, and Qi Long receives support from NIH, PCORI, NSF, AHA, and the Cystic Fibrosis Foundation and served as a consultant for Eisai.
Sandra Jackson received support from Amylin.
After the study reported here was completed, Dr. Phillips founded a company, Diasyst Inc., which aims to develop and commercialize diabetes management programs.
Other authors have no potential conflicts of interest to declare.
This work was supported in part by FDA award RO1FD003527 (L.S.P), VA awards HSR&D IIR 07-138 (L.S.P, S.L.J.), and I01-CX001025 and I01-01BX003340 (L.S.P.), NIH awards R21DK099716 (L.S.P., Q.L., and S.L.J.), DK066204 (L.S.P.), U01 DK091958 (L.S.P. and M.K.R.), U01 DK098246 (L.S.P. and D.E.O.), R21 NS091630 (Q.L.), and a Cystic Fibrosis Foundation award PHILLI12A0 (L.S.P).
© 2018